Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

BMS 245 BMS986489: First Line Extensive Small Cell Lung Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called BMS-986489 (the study drug) is a safe and effective option for patients with extensive-stage small cell lung cancer (ES-SCLC). We want to find out how well it works in comparison to the usual therapy for this diagnosis.

What is the Condition Being Studied?

Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with SCLC
Have extensive-stage disease
Are eligible to receive a platinum-based chemotherapy regimen
Do not have any other malignancy aside from SCLC

For more information about who can be in this study, please contact annemarie.peters@duke.edu.

Grupo etario

Adultos

What is Involved?

Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) a 1 de 2 grupos.

Arm A: If you are assigned to this group, you will get a single infusion of the study drug in combination with chemotherapy (carboplatin plus etoposide) every 3 weeks. After the first 12 weeks (4 cycles of treatment), you will get the study drug on its own every 4 weeks.
Arm B: If you are assigned to this group, you will get a single infusion of atezolizumab in combination with chemotherapy (carboplatin plus etoposide) every 12 weeks. After the first 12 weeks, you will get atezolizumab on its own every 4 weeks.

You will continue to receive your assigned study regimen for as long as you are receiving a positive benefit.

Study Details

Full Title

A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS)

Principal Investigator